South Korea-based drug production company LOTTE BIOLOGICS announced on Monday that it has entered into a late-stage to commercial contract manufacturing partnership with a US-based global biopharmaceutical company.
The partnership covers a late-stage Phase 3 programme that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals.
LOTTE BIOLOGICS said that by aligning with its partner's meaningful pipeline expansion into new therapeutic areas, it will be playing a pivotal role in supporting patient access to innovative medicines.
In accordance with confidentiality obligations, the client's identity has not been disclosed. The term of the contract extends until the middle of 2030.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA